Stock of the Day

Today's Trend

Aurinia Pharmaceuticals, Inc. (AUPH) — Shares are trading higher after quarterly results and forward sales targets. Investors are reacting to a large EPS beat, revenue beats and company guidance for LUPKYNIS sales plus progress on a second drug candidate (aritinercept). Volume is elevated versus average, suggesting active positioning around the news.

• Large EPS and revenue beat — Aurinia reported $1.53 EPS vs. $0.21 consensus and revenue of $77.11M vs. $74.7M est., driving a strong fundamental surprise and improved profitability metrics. Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
• LUPKYNIS momentum & 2026 sales target — Management set 2026 LUPKYNIS sales guidance of $305M–$315M after full‑year sales grew ~25%, giving investors a clearer growth runway for the core product. Aurinia targets $305M–$315M LUPKYNIS sales for 2026 while advancing aritinercept clinical development
• New growth option — Management highlighted progress advancing aritinercept into clinical development as a potential pipeline catalyst beyond LUPKYNIS, which can re-rate the stock if clinical data are positive. Aurinia Results Highlight LUPKYNIS Momentum And New Aritinercept Growth Option
• Earnings call / transcripts available — Investors can review management commentary and Q&A for details on commercialization trends, gross margin drivers and R&D timing; transcripts and the call recording are available. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2025 Earnings Call Transcript
• Short‑interest data appears anomalous — Reports in the feed show zero shares and NaN changes, indicating a likely data error; no clear short‑pressure signal from these entries. (No reliable link available.)

Bottom line for investors: the upside move is driven by a sizable EPS/revenue beat, explicit LUPKYNIS sales targets for 2026 and pipeline progress (aritinercept). Watch management commentary for patient growth trends, gross margins and cadence of clinical updates — those items will determine whether the current re‑rating is durable.